Skip to main content

Table 2 Proportion of controlled patients based on goals from 2018 to 2022

From: Effect of the SARS-CoV-2 pandemic on metabolic control in patients with type 2 diabetes: a 5-year cohort follow-up managed by a dynamic multidisciplinary team in Northeastern Mexico

Parameter in control

Beginning 2018

n(%)

End of 2018

n(%)

Beginning 2019

n(%)

End of 2019

n(%)

Beginning 2020

n(%)

End of 2020

n(%)

Beginning 2021

n(%)

End of 2021

n(%)

Beginning 2022

n(%)

End of 2022

n(%)

p-value1

Fasting Serum Glucose

110

(13.8) n = 796

126 (16.3) n = 775

488

(56.2) n = 869

491 (55.2) n = 889

421

(54.8) n = 768

476 (56.5) n = 843

455

(54.6) n = 833

285 (59.5)

n = 479

378

(50.6) n = 747

407 (56.1)

n = 726

 < 0.001

Glycated Hemoglobin

493

(55.5)

n = 888

308 (53.2)

n = 579

171

(53.8)

n = 318

586 (61.3)

n = 956

261

(64.3) n = 406

96

(73.8)

n = 130

461

(61.7) n = 747

410 (70.8)

n = 579

373

(61.9) n = 603

490 (70.7) n = 693

 < 0.001

HDL-C

415

(62.9)

n = 660

372 (60.1)

n = 619

379

(61.1)

n = 620

401 (59.1)

n = 679

325

(57.2) n = 568

412

(58)

n = 710

361

(55.6) n = 649

157 (50.2)

n = 313

689

(87.0) n = 792

277 (48.6) n = 570

 < 0.001

LDL-C

406

(62.1)

n = 654

403 (66.0)

n = 611

384

(62.2)

n = 617

403 (59.4)

n = 679

298

(52.7) n = 566

387 (55.0)

n = 704

385

(59.0) n = 653

173 (53.2)

n = 325

476

(69.7) n = 683

326 (57.0) n = 572

 < 0.001

Triglycerides

356

(53.9)

n = 660

354 (56.9)

n = 622

338

(53.8)

n = 628

394 (57.1)

n = 690

305

(53.1)

n = 574

389 (54.6)

n = 712

333

(51.2)

n = 650

150 (47.5)

n = 316

322

(53.4)

n = 603

299 (52.5)

n = 570

0.161

Negative

Albuminuria

64

(80.5)

n = 74

263 (83.0)

n = 317

247

(81.0)

n = 305

316 (82.1)

n = 385

208

(86.3) n = 241

230 (75.4)

n = 305

266

(82.4) n = 323

47 (81.0) n = 58

250

(87.4) n = 683

219 (89.0) n = 246

0.002

FIB-4 0–1

Classification

199 (65)

n = 307

67 (46)

n = 145

169 (64)

n = 264

234 (59)

n = 396

79 (72)

n = 110

 < 0.001

FIB-4 2

Classification

93 (30)

n = 307

62 (43)

n = 145

82 (31)

n = 264

129 (33)

n = 396

23 (21)

n = 110

 < 0.001

FIB-4 3–4

Classification

15 (4.9)

n = 307

16 (11)

n = 145

13 (4.9)

n = 264

33 (8.3)

n = 396

8 (7.3)

n = 110

 < 0.001

Systolic blood pressure

563

(82.7)

n = 681

559 (83.4) n = 670

580

(84.8) n = 684

394 (86.6) n = 455

212

(89.8) n = 236

127 (86.4) n = 147

424

(81.1)

n = 523

505 (82.8) n = 610

607

(78.1)

n = 777

640 (80.1)

n = 799

 < 0.001

Diastolic blood pressure

612

(89.6)

n = 683

623 (93) n = 670

625

(91.2) n = 685

417 (91.4) n = 456

211

(89.4) n = 236

135 (91.2)

n = 148

446

(87.1)

n = 512

684 (88.1)

n = 776

684

(88.1) n = 776

729 (91.4)

n = 798

0.01

Body mass index

23

(6.0)

n = 383

30

(7.6)

n = 395

34

(7.0)

n = 486

62

(7.6)

n = 818

53

(7.2)

n = 736

15

(10.1)

n = 148

17

(8.7)

n = 196

43

(14)

n = 297

57

(12)

n = 489

80

(12)

n = 678

 < 0.001

  1. 1p-value obtained by Chi square. A p-value < 0.05 was considered significant. Fasting serum glucose considered in control when within the range of 80—130 mg/dL. Glycated Hemoglobin adequately controlled when < 7%, < 7.5% in adults over 65, and < 8% in adults over 65 with multiple comorbidities. HDL-C considered in adequate control when levels are < 50 mg/dL in women and < 40 mg/dL in men. LDL-C is considered in adequate control when levels are < 100 mg/dL. Triglycerides is considered in adequate control when levels are < 150 mg/dL. Albuminuria is considered negative when levels are < 30 mg/g. FIB-4 is considered in control when classified within the category F0–F1. Systolic blood pressure is considered in adequate control when < 130 mmHg, and diastolic blood pressure is considered in adequate control when < 80 mmHg. BMI considered in adequate control when between 18.5 and 24.9 kg/m2
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us